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ordinary least squares. Percentage change in per-
prescription acquisition cost is regressed on change in the
producer price index for ﬁnished goods, change in the
number of generic and brand-name antiulcer drugs,
change in the number of brand name drugs in the sub-
market (PPIs or H2 antagonist or Carafate), and per-
centage change in the number of generic manufacturers.
RESULTS: The acquisition cost for generic prescriptions
decreases over time. With the exception of Pepcid, the
acquisition costs for H2 drugs rise fairly steadily through-
out the study period. All of the PPIs have rising per-
prescription acquisition costs. For generic drugs, the rise
of number of generic companies has a signiﬁcant negative
impact on generic drug acquisition costs (p = 0.0004).
Neither the change in the producer price index nor any
change in the number of drugs in the drug’s smaller or
wider market has a signiﬁcant impact on acquisition-cost
change (p > 0.10). CONCLUSIONS: The cost beneﬁt to
Medicaid from a rise in competition is being passed on in
terms of lower acquisition costs for generic drugs.
Branded medications continue to show a rise in cost per
script.
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OBJECTIVE: The purpose of this study was to assess the
cost impact of applying VA Criteria for use of non-
steroidal anti-inﬂammatory drugs (NSAID). METHODS:
These criteria utilize a self-administered Gastrointestinal
(GI) Risk Assessment Tool (GI Score). The GI Score is a
composite scale used to predict the 1-year risk level for
an NSAID-associated GI event (no risk to substantial
risk). The risk levels for patients at three facilities were
calculated from VA databases regarding demographic,
prescription, hospitalizations, and active problem lists.
Cost analysis was limited to 2002 VA drug costs and esti-
mated GI-event hospitalization. The perspective was the
VA Healthcare System. We assumed no difference in hos-
pitalized GI event rates between NSAID with a PPI or
COX-2 inhibitor. RESULTS: There were 19,123 NSAID
users at three VA Medical Centers. The following GI
Score risk factors were found in these patients: 212 GI
hospitalization, 212 concurrent warfarin therapy, 725
corticosteroid therapy, and 583 rheumatoid arthritis.
There were 36% over the age of 65. Thirty-two percent
of the patients (n = 6126) were at high risk for a GI event;
8% substantial and 24% signiﬁcant. The actual annual
drug costs for high risk and low risk patients were
$471,898 ($77.02/patient) and $291,960 ($22.46/
patient), respectively. Switching to criteria-based therapy
is estimated to save 14.7 hospitalizations among the high
risk patients. For high risk patients, the base case of
adding a PPI to current therapy with decreased GI-
associated hospitalizations resulted in a cost of $278,809
($45.51/patient/year). We applied alternative therapies
for sensitivity analysis, switching all high risk patients 
to a low-cost NSAID with a PPI ($73,433 or $11.99/
patient/year) or a COX-2 inhibitor ($1,389,686 or
$226.85/patient/year). CONCLUSIONS: Our results
suggest the criteria-based therapy (base case) could result
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OBJECTIVES: Examine optimal cost-effective manage-
ment of adult patients with uninvestigated dyspepsia
(UD). METHODS: We compared the CanDys approach
(acid suppression for patients with heartburn predomi-
nant symptoms, and a test-and-treat strategy for others,
treating H. pylori negative (HP-) patients with acid sup-
pression and HP+ patients with eradication) to empirical
antisecretory therapy (EAS) and prompt endoscopy (PE).
All patients presented with UD. EAS was 4 weeks of
omeprazole 20mg od or ranitidine 150mg bid. The unit
of effectiveness was the proportion of patients symptom-
free (SF) at four weeks. Probability assumptions were
obtained from literature or expert opinion. Direct costs
(in 1999 CAN$) for diagnostic tests, physician visits, and
medications were derived from provincially set fees. The
analysis was conducted using a Monte Carlo simulation
in Data 4.0 that incorporated distributions for all vari-
ables with elasticities greater than 0.3 (for efﬁcacy or
cost). Sensitivity analyses were carried out across clini-
cally relevant ranges of important probability and cost
variables. RESULTS: Of the non-dominated strategies,
